Response to U.S. Supreme Court ruling on mifepristone
Under this ruling, UW Medicine patients will continue to have access to abortion services while the appeals continue, including medication abortion care.
- Susan Gregg, firstname.lastname@example.org, 206-390-3226
- Barbara Clements, email@example.com, 253-740-5043
The U.S. Supreme Court ordered that mifepristone remain widely available while federal appellate cases move forward. Under this ruling, UW Medicine patients will continue to have access to abortion services while the appeals continue, including medication abortion care. UW Medicine reaffirms its support for access to abortion care as part of a full continuum of reproductive healthcare services.
Mifepristone has been approved by the FDA for 23 years and has been shown in numerous clinical studies to be both safe and effective. Mifepristone is also an important medication for the treatment of miscarriage and early pregnancy loss.
The majority of pregnant individuals seeking an abortion in the United States now use medication abortion. UW Medicine fully supports the principle that everyone should have full access to the healthcare services they need, including reproductive care.